drugset / Trial / NCT06097533
Improvement of Quality of Life by Cannabinoids in Oncologic Patients
Phase 2
Recruiting
170 enrolled
University Hospital Schleswig-Holstein
Avextra Pharma GmbH · collabSocraMetrics GmbH · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal is to explore whether the application of cannabis extract Avextra 10/10 solution is suitable to contribute to an improvement in the symptom burden and well-being of oncological palliative care patients. The primary objective of the study is to demonstrate the improvement in global symptom burden in the intervention arm compared to the placebo control group over a period of 12±2 days, as measured by a percentage change in the value of the Edmonton Symptom Assessment System total symptom distress score (ESAS TSDS) at baseline and after 12±2 days.
Timeline
- Start
- 2024-04-08
- Primary completion
- 2026-11-30
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avextra 10/10 | Unknown | — | — |
Indications
No indication recorded.